Skip to main content
TipRanks
Go Ultimate75% OFF

OmniAb (OABI) Approved Products

333 Followers

Approved Products

OmniAb reported approved products of 3 in Q3 2026, unchanged from Q2 2026 and unchanged year over year. The highest value was 3 in Q4 2022.

Counts products that have obtained regulatory approval and can generate recurring sales or royalties, serving as the clearest proof of the platform’s commercial success. Approved products typically convert into steadier revenue and de-risk the business model, while few or no approvals underline reliance on future clinical progress.

2.802.903.003.10Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26Sep 26
Chart Insights

Approved Products has been unchanged for years, indicating OmniAb hasn't added new regulatory approvals to its royalty-bearing portfolio; recent revenue strength therefore stems from upfront/milestone receipts and instrument sales rather than growth in licensed, revenue-generating approved drugs. Management touts expanding clinical programs and rapid phase jumps that create meaningful future upside, but until those programs convert to approvals, revenue will remain lumpy and tied to partner timelines—upside is milestone-led, not recurring royalty-driven.

OABI Approved Products

PeriodApproved Products
Q3 2026Sep 30, 20263
Q2 2026Jun 30, 20263
Q1 2026Mar 31, 20263
Q4 2025Dec 31, 20253
Q3 2025Sep 30, 20253
Q2 2025Jun 30, 20253
Q1 2025Mar 31, 20253
Q4 2024Dec 31, 20243
Q3 2024Sep 30, 20243
Q2 2024Jun 30, 20243
Q1 2024Mar 31, 20243
Q4 2023Dec 31, 20233
Q3 2023Sep 30, 20233
Q2 2023Jun 30, 20233
Q1 2023Mar 31, 20233
Q4 2022Dec 31, 20223

Related KPIs